IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF
|
|
- ありみち ねごろ
- 7 years ago
- Views:
Transcription
1 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment IF20082
2 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF
3
4
5 1945 Iowa Zopf USP USP 40 USP o/w
6 Hydrophilic Ointment Hydrophilic Ointment - 2 -
7
8 pH ph5.5ph g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg
9
10
11
12
13 - 9 -
14
15 5 500g A2X X
16 TEL FAX
17
18
19
20
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
More informationIF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF
2008 2 3 87269 IF19989 100g 700g 30g SucrosePovidoneIodine 1999 3 15 1999 7 9 2000 5 IF 2008 2 IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 1981
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More informationエクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
More information日本標準商品分類番号
2009 10 ( 5 ) 872646 IF 1998 9 1g 0.5mg(0.05%) 0.5mg(0.05%) ifluprednate 0.05 0.05 1994 3 15 2009 9 2000 8 20 FAX IF 2009 7 1 FLUNERT Ointment FLUNERT Cream Difluprednate C27H34F2O7 508.55 6,9-Difluoro-11,17,21-trihydroxy-1,4-
More information001-007 扉・口絵・目次
1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48
More information1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520
More information1 No.236 HP TAXUS
Drug Information News 1 No.236 HP http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/236.pdf TAXUS 186 12 1 1 3050 L 30L 7L 1 (1 ) ( ) 510mm 2 1 2 ph 10 2030 瘙 瘙 瘙 瘙 瘙 瘙 瘙 瘙
More information3 JAS JAS JAS 4
1 2 3 JAS JAS JAS 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ph 102 106 K 31 32 13 3 15 79 33 34 35 36 37 20 6 H.22.3 http://www.caa.go.jp/foods/pdf/syokuhin19.pdf 38
More informationNo.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL)
Drug Information News No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h0925-1.htmL) 2 No.192 HP DI [ ] 1. -1a - 50 100 300 2. 7501500 3000750 1500 3000 60009000 12000240006000 9000 12000 24000
More information取扱説明書[NE-202]
NE-202 13.3 m m 1 2 3 m 4 5 6 7 a a a 8 9 10 11 12 a a a a 13 14 15 16 17 2.4 FH 1/XX 4 18 19 20 21 22 23 24 25 26 27 1 2 3 4 5 6 m 7 h 8 r 9 a P b c d e f g h i j ud k l m n o 28 29 30 31 32 33 34 35
More information14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
More information平成25年度調理師試験問題
25 15 60 HB 2 1 1 2 36 1961 46 1971 56 1981 3 1991 3 4-1 - 5 6 7 8 6 2 12 31 1 15 1 15 4 15 4 15-2 - 9-3 - 10 11 12 13 3-4 - 14 腿 15 16 WHO 22 2010 17 18 1-5 - 19 1 g 4 kcal 4 kcal 9 kcal 9 kcal 20 21
More information: : : : ) ) 1. d ij f i e i x i v j m a ij m f ij n x i =
1 1980 1) 1 2 3 19721960 1965 2) 1999 1 69 1980 1972: 55 1999: 179 2041999: 210 211 1999: 211 3 2003 1987 92 97 3) 1960 1965 1970 1985 1990 1995 4) 1. d ij f i e i x i v j m a ij m f ij n x i = n d ij
More informationグリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
More information橡Taro9-生徒の活動.PDF
3 1 4 1 20 30 2 2 3-1- 1 2-2- -3- 18 1200 1 4-4- -5- 15 5 25 5-6- 1 4 2 1 10 20 2 3-7- 1 2 3 150 431 338-8- 2 3 100 4 5 6 7 1-9- 1291-10 - -11 - 10 1 35 2 3 1866 68 4 1871 1873 5 6-12 - 1 2 3 4 1 4-13
More informationuntitled
2007 12 1 871146 IF 1998 9 350mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 2007 8 31 2007 12 21 1955 2 FAX TEL FAX IF 2007 12 6 IF 1
More informationPowerPoint プレゼンテーション
2006 20042006 2006 2006 2006 20072009 2007 2007 2007 2007 2007 20077 0207 20062007 20062007 2006 06 KV2015KV2015 061730.429.7 03120413.50514.5 07 100 KRN321 07180731.3 2006 1,163 4 06 05 06 06 16,659 102.1%
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More informationw NEWS NEWS Y
No.472 FEB. 200315 w NEWS NEWS Y e r Y E t 1 1 y u i B 1 1 Y c fa g f o p mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr A 1 !0 1 1
More information1999年3月作成(新様式第1版)
200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1
More information-1-19 753-0214 TEL 083-927-7031083-927-7029 FAX 083-927-0214 e-mail a17201@pref.yamaguchi.lg.jp - 2 - -3-. 20kg 60% 2kg 2 3 -4-30 3 15 3-0.05 0.4 NaOH 0.5 20 -5-. 1 1,757g 69% 30 -6- -7- -8- C C H17 18
More information最近の金融経済情勢について
(2001=100 15 5 30 ( ) 1637 2003 3 1.0 70.9 2004 3 () 0.7 15.0 85.5 977 2003 3 2.6 102.4 2658.7 2004 3 () 1.5 17.4 59.0 660 2003 3 0.8 38.1 2004 3 () 0.2 11.4 152.3 3 Slim Safety Specialty 2003
More information第3章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11
More informationA5_Catalog-US-JN_ indd
66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **
More informationレイアウト 1
1 3 6 7 8 3 6 7 8 g mg 6 1 16 16 18 16 13 138 13 16 1 11 8 78 8 17 9 9 g mg 18 13 1 1 1 99 6 3 36 3 3 8 1 18 18 18 16 16 1 1 g mg 1 1 13 13 1 11 11 g mg 8 6 g 1 g mg 93 38 9 93 8 8 176 1 1 1 1 11 18
More information......IF
873959 CEREZYME injection IF20084 MR MR Drug Safety Update IF I. 1 3 2 3 II. 1 4 2 4 3 4 4 4 5 5 6 5 7CAS 5 III. 1 6 2 6 3 6 4 7 5 7 IV. 1 8 2 8 3 8 4 8 5 9 6 9 7 () 9 8 9 9 9 10 9 11 10 12 10 13 10 14
More informationL- 19 L L- L-
0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
More information無印良品 キッチン・テーブル クリーニング・バス用品 2010春夏
200 6 6 7 8 2 4 6 6 7 7 7 2 8 8 9 9 9 20 20 2 22 22 22 24 24 24 25 26 26 28 28 29 29 30 30 3 www.muji.net 32 32 33 34 34 859275 35 39 4 42 35 36 35 37 36 38 39 40 40 40 4 4 42 44 43 45 46 47 47 48 49 50
More information無印良品 キッチン・テーブル・クリーニング・バス用品 2009 春夏
2009 2009 6 6 8 2 4 6 8 8 9 9 9 2 20 20 2 2 2 22 22 22 23 24 25 25 23 26 26 27 27 28 30 30 3 3 32 32 32 www.muji.net 34 34 35 35 35 36 36 37 37 37 38 39 854845 42 43 44 48 38 4 42 42 42 43 43 45 47 46
More information152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg
More informationIF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF
2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF
More informationVol. 4, No
1 0.005 71 2 0.005 72 3 0.005 73 4 0.005 74 5 0.005 KRM 75 6 0.005 76 7 0.005 77 8 0.005 78 9 0.005 79 10 0.005 80 11 0.005 TS 81 12 0.005 TOA 82 13 0.005 83 14 0.005 84 15 0.005 NS 85 16 0.005 86 17 0.005
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More informationMicrosoft Word - 高橋_国試講習会2006m.doc
2006 19 150 20 200 19 80 2 70 1 45 1 1 30 20 105 2 40 1 1 31 95 2 25 1 1 32 1. 2. 3. 4. 5. 1 [] 25 12.5% 2006/3 6 2 1 2 3 7 A a b c d 11 e B a b c d C a b c D a b E a b c d 2 15 16 17 18 19 20 2001 2002
More informationTaro10-mizushima01.PDF
- 1 - ATAGO N- % % g % g % g % g % g % g Brix% g g ml ml mgm / l ml mg mol/l mol/l mol/l ph NaSO mol/ l ml / g mg mg ml mol/l ml ml L- L- FIBE-MINI FIBE-MINI % % FIBE-MINI % g % g % g % C mg mg mg
More information青森県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5
More information2
107-0062 2-2-8 DF 6F TEL 03-4530-9268 FAX 03-6893-0901 2 2000 3 BtoB BtoC 4 3 5 TOP USP 6 TOP USP= A B 7 30% 1.3 8 A A A A B 9 A A 20 10 11 http://www.3c-s.jp/service/mystery_shopper.html http://www.3c-s.jp/contact/index.html
More information中学校学習指導要領解説数学編
20 1 1 3 7 16 16 16 22 31 31 40 67 67 67 77 87 93 98 104 104 109 117 121 124 129 129 140 149 152 155 161 161 163 168 170 -1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -16- -17- -18- -19- -20- -21-
More informationタミフルインタビューフォーム
2008 1 20 87625 IF 1998 9 75 3% 2 1 75mg 1 g 30mg Oseltamivir Phosphate 2000 12 12 2001 2 2 2001 2 2 2002 1 17 2002 4 26 2002 7 31 IF 2008 1 O H 2 N O H O CH 3 H 3 C N H H 3 PO 4 H H O H 3 C CH 3
More information20●12頁●6-14▲放射線科▲.ppt
No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%
More informationEL-G37
EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.
More information(1) 3 (2) (3) (5) (7) (1) 65P00010 (4) (6) 81M00020 1 2 3 4 1-2 1-16 1-22 2-2 3-2 3-17 3-20 3-24 3-30 3-39 3-45 3-53 3-63 3-105 4-2 4-12 4-14 4-24 4-29 5 6 7 8 9 4-38 4-71 4-73 5-2 5-22 5-33 6-2 6-9
More informationテクノ東京21 2003年6月号(Vol.123)
2 3 5 7 9 10 11 12 13 - 21 2003 6123 21 2003 6123 - 21 2003 6123 21 2003 6123 3 u x y x Ax Bu y Cx Du uy x A,B,C,D - 21 2003 6123 21 2003 6123 - 21 2003 6123 - 21 2003 6123 -- -- - 21 2003 6123 03 3832-3655
More information12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
More information1 2 3 1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 % 23 24 25 26 27 28 29 30 31 32 33 34 35 4 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68
More information0.01mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.05 mg/ ç 0.05 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.0005mg/ ç 0.0005mg/ ç 0.02 mg/ ç 0.02 mg/ ç 0.002 mg/ ç 0.002 mg/ ç 0.004 mg/ ç 0.004 mg/ ç 0.02 mg/ ç 0.02 mg/
More information(1) 3 (2) (3) (5) (7) (1) 65P00010 (4) (6) 81M00020 1 2 3 4 1-2 1-16 1-22 2-2 3-2 3-17 3-20 3-24 3-30 3-39 3-45 3-53 3-63 3-104 4-2 4-12 4-14 4-26 4-29 5 6 7 8 9 4-34 4-43 4-64 4-67 5-2 5-22 5-34 6-2
More informationuntitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
More informationuntitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
More information橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
More information<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
More informationMicrosoft Word - 観光と食 2・3 食品添加物 vs. 質の事業.doc
2 1. Ø 90 15 100 130 3 Ø Ø Ø Ø Ø ph Ø Ø ph Ø Na Na CMC OKINAWA UNIVERSITY 1/13 Na Na V.C ph ph Ø C g mg Ø ml g Ø Ø V.C g C mg 50kcal g Ø OKINAWA UNIVERSITY 2/13 Ø Ø Na Ø Ø Ø Ø Ø Ø Ø 1. 2. 3. 4. Ø OKINAWA
More informationuntitled
(No.001No.003) (No.004No.007) (No.008No.011) (No.012) (No.013No.014) (No.015No.017) (No.018No.022) (No.023No.026) (No.027No.028) (No.029No.032) (No.033No.034) (No.035No.037) (No.038) No.001 (1) (2) :VOD
More informationCW3_AX056A01.indd
165 166 167 168 169 170 A 171 172 173 174 175 176 177 178 179 ritalin http://www.ncnp.go.jp/nimh/yakubutsu/drug-top/data/ researchjhs.pdf 180 mg mg http://www.novartis.co.jp/product/rit/te/te_rit. html
More information取扱説明書
B6FJ-7351-01 LIFEBOOK PH .................................................... 5.................................................................. 8....................................................................
More informationAS1161 : K21
2012 AUTUMN & WINTER CATALOG AS1161 : K21 AS3432 : A28 AS1157 : S83 AS1842 : K23 AS3433 : K25 AS1953 : A28 AS1730 : K25 AS3435 : K27 AS3434 : S83 AS3431 : N27 AS1159 : L04 AX1029 : C02 RX0044 : W06 AX1031
More informationA B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
More information13 3 21 11 60 11 3 10 13 3 21 11 3 10 38 11 7 23 1 11 11 12 39 12 2 29 2 12 3 15 40 12 8 30 3 12 11 2 41 13 2 20 4 13 3 15 42 13 3 15 10 14 16 1900 1945 1985 ( ) ( ) 1 2 6 2 Thiobacillus SO 2-4 H 2 S
More information20 57
56 20 57 58 59 12 60 ph 61 62 CCA 63 64 ( 1) 700 7.5 86% 54 17 71 2) 700 6.8 86% 50 15 65 3) 600 700 5.7 84% 36 14 50 550 650 4.2 80% 21 6 27 40 500 3.6 78% 16 7 23 3.6 78% 16 7 23 400 700 4.0 78% 18 7
More informationCD納品用.indd
1. 1.1 1.2 1.3 1.4 2. 3. 3.1 3.2 3.3 4. 4.1 4.2 6. Journal of the Institute of Nuclear Safety System Journal of the Institute of Nuclear Safety System Journal of the Institute of Nuclear Safety System
More information卓球の試合への興味度に関する確率論的分析
17 i 1 1 1.1..................................... 1 1.2....................................... 1 1.3..................................... 2 2 5 2.1................................ 5 2.2 (1).........................
More information宮城県2012-初校.indd
2012 MIYAGI http://www.kairyudo.co.jp/ 3 6 8 1415 16 1 2 3 3 4 5 6 7 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 8 1 2 3 9 1 2 3 50kg 55kg 60kg 66kg 73kg 81kg 90kg 90kg 44kg
More informationNo.19
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
More information,889 99, , , ,031 8,952 13,261 16,443 14,464 17,948 % ,037 8,848 10,927
2013 2013 3 3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575
More information22
2015 75 7074 6569 2064 26470 21 22 4,060 1,330 23 24 15,000 80 24,600 15,000 15,000 24,600 15,000 24,600 15,000 24,600 37,200 145 520 383 44,400 25 26 280 160280 280 346 160 80 160 37,200 24,600 15,000
More informationFELTCOVER.ai
OWNERS MANUAL OWNERS MANUAL www.riteway-jp.com FOR YOUR SAFETY AND CONFORT, IF YOU ARE ALIEN WHO LIVE IN JAPAN, PLEASE ASK SOMEONE WHO UNDERSTAND THIS MANUAL TO MAKE DETAILED EXPLANATION FOR YOU. MINIMUM
More information02
Q A Ax Pb Ni Cd Hg Al Q A Q A Q A 1 2 3 2 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 8 0 0 1 2 3 4 1 0 1 2 Q A ng/ml 4500 D H E A 4000 3500 3000 2500 2000 DHEA-S - S 1500 1000 500 0 10 15 20 25 30 35 40 45
More information2015taisetumatome.rtf
B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4
More informationまえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
More information02 2002 02 292,87300 0231 0049.102 40 10 30 80 2008 2010 80 02 12 03 50 93 51 02 40 02 8.27 02 27 0212 2.16 32 1116 Heinz02 03 02 919901 9398 02 0310 16 0 3 5,354 1,330 70 51.2 70 36.9 45.841.8 99 76.9
More informationEA_O_IF_1308_04.indb
2013 年 10 月 作 成 ( 改 訂 第 4 版 ) 日 本 標 準 商 品 分 類 番 号 872649 医 薬 品 インタビューフォーム IF 2013 外 用 ビタミンE A 剤 ビタミンE A 製 剤 剤 形 製 剤 の 規 制 区 分 規 格 含 量 一 般 名 製 造 販 売 承 認 年 月 日 薬 価 基 準 収 載 発 売 年 月 日 開 発 製 造 販 売 ( 輸 入 ) 提
More information> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3
13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >
More information2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
More information2011 2011 2011 100/m 0.003/ 0.0005 / 0.01/ 0.01 / 0.01/ 0.05 / 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005
More informationI
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
More informationClean, Health, Safety http://www.koken-ltd.co.jp/product/safe/general/ http://www.koken-ltd.co.jp/product/safe/emergency/ Step1 Step1 Step2 Step3 Step2 Step3 Q A Q A TEL: 03-5276-1932 FAX:03-5276-6530
More information4 4 θ X θ P θ 4. 0, 405 P 0 X 405 X P 4. () 60 () 45 () 40 (4) 765 (5) 40 B 60 0 P = 90, = ( ) = X
4 4. 4.. 5 5 0 A P P P X X X X +45 45 0 45 60 70 X 60 X 0 P P 4 4 θ X θ P θ 4. 0, 405 P 0 X 405 X P 4. () 60 () 45 () 40 (4) 765 (5) 40 B 60 0 P 0 0 + 60 = 90, 0 + 60 = 750 0 + 60 ( ) = 0 90 750 0 90 0
More information